IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71) (vol 48, pg 703, 2005) by Bottazzo, G, Bosi, E, Cull, C, Bonifacio, E, Locatelli, M, Zimmet, P, Mackay, I, Holman, R

Erratum: IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71) (Diabetologia (2005) 48 (703-708) DOI: htt... by Bottazzo, G, Bosi, E, Cull, C, Bonifacio, E, Locatelli, M, Zimmet, P, Mackay, I, Holman, R

IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). by Bottazzo, G, Bosi, E, Cull, C, Bonifacio, E, Locatelli, M, Zimmet, P, Mackay, I, Holman, R

Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). by Davis, T, Wright, A, Mehta, Z, Cull, C, Stratton, I, Bottazzo, G, Bosi, E, Mackay, I, Holman, R

Autoantibodies to JA2ic and to Phogrin increase the prediction for insulin requirement in patients with Type 2 Diabetes by Bosi, E, Locatelli, M, Cull, C, Scirpoli, M, Bobifacio, E, Stratton, I, Holman, R, Bottazzo, G, Grp, U

Inappropriate HLA class II expression on epithelial cells: new insight in the pathogenesis of distinctive autoimmunity. by Bottazzo, G, Londei, M, Bosi, E, Mirakian, R, Belfiore, A, De Berardinis, P, Todd, I, Pujol-Borrell, R, Feldmann, M